SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 33128
  • 2
    Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 210311
  • 3
    Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 227181
  • 4
    Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 358490
  • 5
    Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 44956
  • 6
    Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 374348
  • 7
    Shepard R, Rini B, Garcia JA et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26: abstract 5123
  • 8
    Di Lorenzo G, Carteni G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 446974
  • 9
    Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182: 2934
  • 10
    Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 617
  • 11
    Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 137378
  • 12
    Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 816
  • 13
    Richter S, Pfister D, Thur D, Engelmann UH, Heindenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2008; 31: 234; abstract v684
  • 14
    Choueiri TK, Brick AJ, McDermott D et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol 2008; 19: viii191; abstract 593P
  • 15
    Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 3504
  • 16
    Escudier B, Ravaud A, Oudard S et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann Oncol 2008; 19: viii45; abstract 72O
  • 17
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516
  • 18
    Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1624
  • 19
    Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 251624
  • 20
    Jonasch E, Corn P, Pagliaro LC et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 5765
  • 21
    Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 127280
  • 22
    Bellmunt J, Maroto-Rey P, Trigo JM et al. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol 2010; 12: 5038
  • 23
    Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 250512
  • 24
    Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl 2007; 5: 300; abstract 4506
  • 25
    Heuer R, Eichelberg C, Zacharias M, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib. Eur Urol Suppl 2009; 8: 183; abstract 251
  • 26
    Sepulveda J, Maroto P, Andres R et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. J Clin Oncol 2008; 26: abstract 16100
  • 27
    Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 91730
  • 28
    Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 22031
  • 29
    Gerullis H, Bergmann L, Maute L et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2009; 27: 3738
  • 30
    Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev 2009; 36: 1623
  • 31
    Rawlins M. Harveian Oration 2008. De Testimonio. On the evidence for decisions about the use of therapeutic interventions. Available at: http://bookshop.rcplondon.ac.uk/details.aspx?e=262. Accessed April 2011